Ziphius Vaccines NV articles

Background

Outbreaks of multiple Flaviviruses have afflicted humankind for centuries due to their rapid spread predominantly by arthropod vectors. Global warming has caused epidemics to emerge in previously unaffected regions. The SARS-CoV-2 outbreak and subsequent race in vaccine development can provide strategies to the scientific community to avoid a flavivirus pandemic.

The COVID-19 battle led to the first-time authorization of messenger ribonucleic acid (

Self-amplifying RNA vaccines may induce equivalent or more potent immune responses at lower doses compared to non-repli-
cating mRNA vaccines via amplified antigen expression. In this paper, we demonstrate that 1 mg of an LNP-formulated dual-
antigen self-amplifying RNA vaccine (ZIP1642), encoding both the S-RBD and N antigen, elicits considerably higher neutral-
izing antibody titers against Wuhan-like Beta B.1.351 and Delta B.1.617.2 SARS-CoV-2 variants compared to those of c